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introduction
Chromosomal translocations are a hallmark of haematological
malignancies and present as clonal abnormalities in both
leukaemias and lymphomas. Whilst these chromosomal
aberrations were initially described with cytogenetic techniques,
the genes involved have in most instances been cloned and
their functions well characterized.
In more recent times, molecular abnormalities have been
discovered in leukaemia and lymphoma which largely escape
detection through classical and molecular cytogenetics. A good
example to illustrate this field are acute myeloid leukaemias
(AMLs) with a ‘normal’ karyotype [1], which will be a focus of
this review. Information has largely been collected from recent
authoritative reviews available in this field, and from a few very
selected and recent original articles; readers interested in
a broader collection of original papers are asked to consult the
references in the summary articles.
pathology of transcription factor genes
CEBPA
The main role of the transcription factor CCAAT/enhancer
binding protein a (CEBPA) in haematopoiesis is the
development of mature granulocytes. Disruption of CEBPA
accordingly results in a blockade of early granulocyte
maturation. Molecular studies as well as mouse models
suggest that whilst disrupting the cell-cycle regulatory function
of CEBPA may be sufficient to initiate AML-like
transformation, other CEBPA functions must be preserved in
leukaemic stem cells.
Clinically, AML patients with CEBPA mutations enjoy
a longer relapse-free or overall survival than patients with other
molecular abnormalities, although the reason for this remains
unclear. The majority of AML patients have more than one
CEBPA mutation [2, 3]. Among patients with a single CEBPA
mutation, the predominant types are frameshift N-terminal
mutations (40%) or in-frame C-terminal insertion/
deletion mutations (30%). Patients with multiple CEBPA
mutations mainly show the combination of one N-terminal
frameshift mutation and one C-terminal in-frame mutation,
with the two mutations typically being located on different
alleles. This may explain why additional genetic abnormalities
are hardly ever identified in AML patients with CEBPA
mutations, since the most frequent ‘second’ genomic abnormality
in such patients is an additional mutation in the very same gene.
These observations indicate that one CEBPAmutation might
predispose to the occurrence of an additional CEBPAmutation as
a secondary hit, ultimately inducing AML. This would also be
consistent with the observation that both CEBPAmutation types
do not develop at the time of relapse, indicating that CEBPA
mutations are a primary event in the pathogenesis of AML rather
than being involved in disease progression.
AML1–ETO
Dysregulated expression rather than gene mutation is another
mechanism to disrupt function of transcription factors crucial
for normal haematopoiesis [3–5]. CEBPA mRNA expression is
suppressed in the presence of the AML1–ETO fusion protein
both in vitro and in vivo. The leukaemic fusion protein AML1–
ETO, i.e. the product of the chromosomal translocation
t(8;21)(q22;q22), occurs frequently in human AML with
granulocytic differentiation. AML with t(8;21) tends to occur in
early adulthood and has a better prognosis than most other
types of AML. Morphologically, it shows enhanced marrow
granulopoiesis with inhibition of erythropoiesis. Blasts display
with solitary Auer rods and abnormal myelocytes with
increased cytoplasmic granulation.
The AML1–ETO fusion protein comprises a moiety from the
haematopoietic transcription factor RUNX1 (also known as
AML1), on chromosome 21, which is joined to the majority of
the ETO repressor protein, encoded on chromosome 8. RUNX1
normally functions as a transcriptional activator, promoting
granulocytic differentiation through the coordinated
upregulation of lineage-specific target genes such as
myeloperoxidase. ETO is a scaffolding factor for the assembly
of protein complexes. Through the fusion with ETO, RUNX1
function changes from activator to repressor, and thus AML1–
ETO predictably acts as a transcriptional repressor for RUNX1
target genes at several nodal points during haematopoietic
differentiation. As a consequence, AML patients with t(8;21)
have much less CEBPA mRNA than AML with a normal
karyotype, and AML1–ETO is thought to inhibit CEBPA
mRNA expression through inhibition of autoregulation.
Through the repression of several key haematopoietic
transcription factors, AML1–ETO may thereby expand stem
cell pools. In addition, repression of genes involved in DNA
base excision repair conveyed by AML1–ETO may promote
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genetic instability within this expanded stem cell pool. In
particular, lineage commitment defects induce expansion of
a self-renewing progenitor compartment, which may then
result in leukemic transformation through additional
mutations.
the nuclear factor-kB pathway in
lymphoma
Mediastinal large B-cell lymphoma (MLBCL) is a subtype of
diffuse large B-cell lymphoma (DLBCL) that characteristically
presents as a localized tumour in the mediastinum of young
females. Although MLBCL has distinctive pathologic features, it
clinically resembles the nodular sclerosis subtype of classical
Hodgkin’s lymphoma (cHL). Primary MLBCLs express low
levels of B-cell receptor signalling pathway components and
exhibit a distinctive cytokine signature, strikingly similar to
those of cHL. In cHL, activation of the nuclear factor-jB (NF-
jB) pathway enhances the survival of surface immunoglobulin-
negative Reed–Sternberg cells. Gains in chromosome 2p found
in 20% of MLBCL and up to 50% of cHL, are associated with
amplification of the REL locus, which encodes an NF-jB
subunit, and thus may represent one potential mechanism for
increased NF-jB activity and tumour cell resistance to
apoptosis [6–10].
The constitutive activation of the transcription factor NF-jB
is a hallmark of many highly malignant tumours. NF-jB
regulates many genes for immune response, cell adhesion,
differentiation, proliferation, angiogenesis as well as apoptosis,
and it delivers strong anti-apoptotic stimuli to cells. NF-jB
transcription factors are kept in an inactive state in the
cytoplasm, but signalling through various cell surface receptors
leads to nuclear accumulation of NF-jB which in turns elicits
upregulation of several NF-jB target genes. Whereas in most
germinal centre (GC) B cells, there is low activity of the NF-jB
pathway, GC-derived lymphomas use several strategies to
overcome the physiological propensity of normal GC cells to
undergo apoptosis. These may include NF-jB gene point
mutations which release NF-jB for transfer into the nucleus
(cHL), or latent membrane protein 1 in Epstein–Bar virus
(EBV)-associated lymphomas which activates NF-jB.
Constitutive activation of the NF-jB pathway in lymphoma
leads to nuclear localization of the protein, a prerequisite to set
its downstream pathway into motion.
The known role of NF-jB activation in cHL and the
increased expression of certain NF-jB target genes in
primary MLBCLs prompted further investigation of this
survival pathway in MLBCL. In almost all cases, c-REL was
localized to the nucleus, indicating that the NF-jB survival
pathway was constitutively active in these tumours.
Functional assays confirmed that MLBCL cell lines exhibited
increased constitutive NF-jB activity and relied upon the
NF-jB pathway for survival. Therefore, the MLBCL
transcriptional profile already seems to be translating into
a functionally relevant immunohistochemical signature in
this disease. As specific NF-jB inhibitors become available
for clinical trials, MLBCL should be rapidly targeted for
further evaluation.
nucleophosmin protein aberrations
Nucleophosmin protein 1 (NPM1) is an abundant and highly
conserved phosphoprotein that normally resides in nucleoli
and shuttles between nucleus and cytoplasm. NPM1 has a role
in various cellular processes, including ribosome biogenesis,
response to stress such as UV irradiation and hypoxia,
maintenance of genomic stability, regulation of activity and
stability of tumour suppressor genes such as p53 and ARF, and
transcriptional regulation.
NPM1 mutations can be identified in about half of patients
with cytogenetically normal AML and thus are the most
frequent genetic change in this patient subset [2, 11]. Mutations
in NPM, particularly those placed in exon 12, result in
abnormal cytoplasmic localization of NPM1 protein.
Cytoplasmic accumulation of NPM1 mutants is caused by two
major alterations acting in concert: (i) loss of tryptophan
residues normally required for NPM1 binding to the nucleoli,
and (ii) generation of an additional nuclear export signal motif
at the C-terminus by the exon 12 mutation. Moreover, NPM1
leukaemic mutants may recruit wild-type NPM1 from nucleoli
to nucleoplasm and cytoplasm through dimerization.
NPM1 mutations are associated with several pretreatment
characteristics of patients with cytogenetically normal AML,
including predominantly female sex, higher bone marrow blast
content, higher white blood cell and platelet counts, as well as
high CD33-antigen expression but low or absent CD34-antigen
expression. Clinical data on the prognostic impact of NPM1
mutations have been somewhat controversial. Whereas in some
studies there was a significant effect on complete remission rate,
relapse-free survival and event-free survival, other studies
revealed no significant differences in these parameters. NPM1
mutation appears to be a favourable prognostic marker, but
only in the absence of FLT3-ITD (see below), whilst the
presence of NPM1 mutations has no influence on the adverse
prognosis in patients with FLT3-ITD. Approximately 40% of
patients with NPM1 mutations also carry FLT-ITD.
tandem duplications of tyrosine kinase
genes
The receptor tyrosine kinase FMS-like tyrosine kinase-3 (FLT3)
and its ligand are important for the proliferation and
differentiation of early haematopoietic progenitor cells. In
patients with AML, somatic mutations that result in the
constitutive activation of FLT3 have been identified in two
functional domains of the receptor, the juxtamembrane
domain and the split tyrosine kinase domain [2, 12].
Specifically, one mutation type is characterized by internal
tandem-duplications (ITDs) of particular excerpts of the gene.
Activating mutations of the FLT3 receptor occur in 30% of
AML. FLT3 mutations trigger downstream signalling pathways
including RAS-MAP/AKT kinases and signal transducer and
activator of transcription-5 (STAT5). FLT3-ITD mutations
start a cycle of genomic instability whereby increased reactive
oxygen species production leads to increased DNA double
strand breaks and repair errors that may explain aggressive
AML in FLT3-ITD patients.
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From a clinical perspective, FLT3 mutations are relevant
because of their prognostic impact, and because constitutively
active FLT3 may be an attractive target for molecular therapy.
Patients with cytogenetically normal AML harbouring FLT3-
ITD have a significantly inferior outcome compared with
patients without FLT3-ITD, although the prognostic relevance
of FLT3 mutations remains somewhat controversial. Currently,
there are a number of FLT3 inhibitors at various stages of
clinical development. When used as single agents, these
compounds unfortunately have limited activity in AML with
mutant FLT3. Data look more promising when these inhibitors
are combined with conventional chemotherapy. Results from
clinical trials will tell us whether inhibition of mutant FLT3 will
be a successful targeted approach for these patients.
aberrations of microRNA in tumour
cells
In contrast to most haematological malignancies, the neoplastic
lymphoid cells in B-cell chronic lymphocytic leukaemia (CLL)
mostly show chromosomal deletions or loss of heterozygosity
(LOH) rather than translocations. It was therefore suspected
for a long time, that in analogy to solid cancers, eventually
tumour suppressor genes inactivated through the classical
‘Knudson’ mechanism would be found in CLL. However, they
proved pretty elusive. For example, detailed genetic analyses
failed to demonstrate the consistent involvement of any of
genes located in or close to a region at 13q14.3, which is
frequently deleted in B-cell CLL. Instead, another molecular
principle has now been discovered that seems to operate in
CLL. MicroRNAs (miRNAs) have been linked to the initiation
and progression of CLL. A cluster of two miRNAs, MIRN15A
and MIRN16-1, is located exactly inside the minimal region of
loss at 13q14, and both genes are deleted or downregulated in
the majority of CLL samples [13, 14].
MiRNAs are a group of small non-coding RNA molecules
distinct from but related to small interfering RNAs (siRNAs)
that have been identified in a variety of organisms. These small
19- to 24-nucleotide (nt) RNAs are transcribed as parts of
longer molecules named pri-miRNA, several kilobases (kb)
in length, that are processed in the nucleus into hairpin RNAs
of 70–100 nt named pre-miRNA by the double-stranded
RNA-specific ribonuclease. The hairpin RNAs are transported
to the cytoplasm, where they are digested by a second double-
stranded-specific ribonuclease. In animals, single-stranded
miRNA binds specific messenger RNA (mRNA) through
sequences that are significantly, though not completely,
complementary to the target mRNA, mainly to the 3#
untranslated region. By a mechanism that is not fully
characterized, the bound mRNA remains untranslated,
resulting in reduced levels of the corresponding protein.
Alternatively, in some cases bound mRNA can be degraded,
resulting in reduced levels of both the corresponding transcript
and protein. The number of miRNAs is growing rapidly. Today
the number of miRNAs, including those electronically cloned,
is >1000 and still growing.
The function of most miRNAs is not known. In spite of this,
for a few members the participation in essential biological
processes for the eukaryotic cell is proven. The list of proposed
functions includes haematopoietic B-cell lineage fate (miR-
181), B-cell survival (miR-15a and miR-16-1) and cell
proliferation control (miR-125b and let-7). The direct evidence
of the involvement of miRNAs in a human disease came from
the link between miR-155 and B-cell CLL. MIRN15A and
MIRN16-1 form a small cluster at chromosome 13q14.3. Both
genes are ubiquitously expressed as non-coding RNAs (miR-
15a and miR-16-1), with highest levels in normal CD5+
lymphocytes, highlighting their relevant role in normal CD5+
B-cell homeostasis. The majority of CLL patients present
a downregulation of MIRN15A and MIRN16-1 expression
correlating with homozygous LOH at 13q14.3. The two-hit
inactivation model of tumour-suppressor genes applies
unequivocally to the MIRN15A/MIRN16-1 locus per se, as one
allele can be deleted by heterozygous LOH and the second may
be eliminated by a germline mutation in a region which
compromises its procession. E-mil-miR-155 transgenic mice
initially exhibit a pre-leukaemic pre-B-cell proliferation evident
in spleen and marrow, followed by frank B-cell malignancy.
These findings indicate that the role of miR-155 is to induce
polyclonal lymphoid expansion, enhancing the chance capture
of secondary genetic changes for full transformation. Currently
collective evidence strongly indicates a role for miRNAs in
haematological cancers.
haploinsufficiency of genes encoding
ribosomal subunits in myelodysplastic
syndrome
Patients with a 5q– myelodysplastic syndrome (MDS) or 5q–
syndrome have severe macrocytic anaemia, normal or
elevated platelet counts, normal or reduced neutrophil counts,
erythroid hypoplasia in the bone marrow and hypolobated
micromegakaryocytes. They also have a propensity to progress
to AML, although more slowly than other forms of MDS. The
5q– MDS shows a remarkable response to treatment with the
thalidomide analogue lenalidomide.
No patients with 5q– MDS were reported to have biallelic
deletions within a common deleted region (CDR) on 5q, and
no point mutations were found in the remaining allele of any of
the genes in this region. Thus, the 5q– syndrome was suspected
to be caused by protein haploinsufficiency which is a loss of
only one allele at a given locus, implicating reduced protein
expression from the remaining single allele, i.e. a reduction in
gene dosage. Data from both mouse models and human
tumours point out that allelic heterozygosity, leading to protein
haploinsufficiency, may in fact convey tumour predisposition
and progression. An elegant report very recently pointed out
that the principal hallmarks of 5q– MDS (erythroid maturation
block with preservation of megakaryocyte differentiation) can
be recapitulated experimentally with short hairpin RNAs
(shRNAs) targeting each of the genes within the CDR [15, 16].
Partial loss of function, or haploinsufficieny of a gene called
RPS14 in fact recapitulates the phenotype of the 5q– syndrome.
RPS14 is a component of the 40S ribosomal subunit. Decreased
expression of RPS14 results in an accumulation of the 30S pre-
rRNA species with a concomitant decrease in 18S/18SE rRNA
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levels which is consistent with reports that RPS14 is specifically
required for the processing of 18S pre-rRNA.
The same genetic principle also operates in a familial
autosomal dominant platelet disorder with predisposition to
AML [17]. These families show germline heterozygous
nonsense mutations or intragenic deletion of one allele of the
haematopoietic transcription factor CBFA2 (formerly AML1).
Bone marrow or peripheral blood cells from affected
individuals shows a decrement in megakaryocyte colony
formation, demonstrating that CBFA2 dosage affects
megakaryopoiesis. These findings support a model for this rare
disorder where haploinsufficiency of CBFA2 causes an
autosomal dominant congenital platelet defect and
predisposes to the acquisition of additional mutations that
cause leukaemia.
conclusion
In summary, the molecular pathology of leukaemias and
lymphomas has today been extremely well worked out,
including as it were a great potential for the development of
new ‘targeted’ treatments (to use a fashionable phrase). The
extraordinary success story of imatinib mesylate treatment
in chronic myelogenous leukaemia will still have to be
matched in other malignancies, but a number of approaches
are on the way that may eventually prove to be equally
rewarding.
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